SCHEMBL2023735

SCHEMBL2023735

O=C(O)N1CCc2sccc2C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.51
AKR1C3 P42330 1/20 0.47
PRMT5 O14744 2/20 0.45
WDR77 Q9BQA1 2/20 0.45
SLC6A4 P31645 2/20 0.41
SLC6A2 P23975 1/20 0.41
CYP2C19 P33261 3/20 0.40
DRD1 P21728 3/20 0.40
ABCB11 O95342 2/20 0.40
ADRA2A P08913 2/20 0.40
CYP2B6 P20813 2/20 0.40
OPRM1 P35372 2/20 0.40
OPRK1 P41145 2/20 0.40
HTR2B P41595 2/20 0.40
KCNH2 Q12809 2/20 0.40
THRB P10828 1/20 0.40
NR1I2 O75469 1/20 0.40
CHRM2 P08172 1/20 0.40
HTR2A P28223 1/20 0.40
P2RY12 Q9H244 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12810928 0.90 AKR1C3 (0.45) HSP90AA1AKR1C3PRMT5WDR77SLC6A4
SCHEMBL5425390 0.88 PNMT (0.58) HSP90AA1AKR1C3PRMT5WDR77SLC6A4
SCHEMBL28890035 0.87 HSP90AA1 (0.46) HSP90AA1AKR1C3PRMT5WDR77SLC6A4
SCHEMBL21899394 0.86 HSP90AA1 (0.55) HSP90AA1AKR1C3PRMT5WDR77DRD1
SCHEMBL4253684 0.84 HSP90AA1 (0.50) HSP90AA1AKR1C3PRMT5WDR77SLC6A4
SCHEMBL8680487 0.84 NOTUM (0.57) HSP90AA1AKR1C3PRMT5WDR77SLC6A4
SCHEMBL2962273 0.84 HSP90AA1 (0.50) HSP90AA1AKR1C3PRMT5WDR77SLC6A4
SCHEMBL19722818 0.84 HSP90AA1 (0.50) HSP90AA1AKR1C3PRMT5WDR77SLC6A4
SCHEMBL31486299 0.83 HSP90AA1 (0.41) HSP90AA1AKR1C3PRMT5WDR77SLC6A4
SCHEMBL3992345 0.82 HSP90AA1 (0.52) HSP90AA1AKR1C3PRMT5WDR77ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4596555-A1 ABHD6 ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2025-08-06 EP claimed
WO-2024071398-A1 ABHD6 ANTAGONIST 小野薬品工業株式会社 2024-04-04 WO claimed
US-20260083735-A1 ABHD6 ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2026-03-26 US disclosed
EP-4596555-A1 ABHD6 ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2025-08-06 EP disclosed
WO-2024071398-A1 ABHD6 ANTAGONIST 小野薬品工業株式会社 2024-04-04 WO disclosed
CN-112159401-A Biased agonist and medical application thereof 中国人民解放军军事科学院军事医学研究院 2021-01-01 CN disclosed
CN-107922430-B 2-substituted benzimidazole-4-formamide compound and preparation method and application thereof 中国科学院上海药物研究所 2020-09-04 CN disclosed
WO-2020132378-A2 COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS COMPRISING DEPRESSION GLIAPHARM SA (CH) 2020-06-25 WO disclosed
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 EP disclosed
US-7968719-B2 Indazole derivatives as inhibitors of hormone sensitive lipase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-06-28 US disclosed
US-7858785-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 US disclosed
US-20090215824-A1 INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE SENSITIVE LIPASE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-08-27 US disclosed
US-7528155-B2 Indazole derivatives as inhibitors of hormone sensitive lipase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-05-05 US disclosed
WO-2009049028-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS TARGEGEN INC. (US) 2009-04-16 WO disclosed
CN-101068804-A Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use TRANSTECH PHARMA INC (US) 2007-11-07 CN disclosed
EP-1831207-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-09-12 EP disclosed
WO-2006066172-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2006-06-22 WO disclosed
US-20050197348-A1 Indazole derivatives as inhibitors of hormone sensitive lipase AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-09-08 US disclosed
US-4147787-A ANTICOAGULANTS PARCOR (FR) 1979-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PLK1, TYMP, TK2 HSP90AA1 2038/4885AKR1C3 2685/4885PRMT5 671/4885
US-20090215824-A1 INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE SENSITIVE LIPASE LIPE, PNLIP, CEL HSP90AA1 744/4885AKR1C3 1505/4885PRMT5 1683/4885
US-20050197348-A1 Indazole derivatives as inhibitors of hormone sensitive lipase LIPE, PNLIP, CEL HSP90AA1 744/4885AKR1C3 1505/4885PRMT5 1683/4885
US-20260083735-A1 ABHD6 ANTAGONIST ABHD6, ABHD16A, ABHD12 HSP90AA1 916/4885AKR1C3 1262/4885PRMT5 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.